1. Liver-specific T regulatory type-1 cells program local neutrophils to suppress hepatic autoimmunity via CRAMP.
- Author
-
Umeshappa CS, Solé P, Surewaard BGJ, Yamanouchi J, Mohapatra S, Uddin MM, Clarke R, Ortega M, Singha S, Mondal D, Yang Y, Vignali DAA, Serra P, Kubes P, and Santamaria P
- Subjects
- Animals, Antigens metabolism, B-Lymphocytes, Regulatory immunology, Cell Polarity genetics, Cytokines metabolism, Gene Expression Regulation, Inflammation pathology, Kupffer Cells metabolism, Liver pathology, Mice, Inbred C57BL, Mice, Inbred NOD, Mitosis genetics, Myeloid-Derived Suppressor Cells immunology, Neutrophil Infiltration, Neutrophils, Organ Specificity, Phenotype, Transcription, Genetic, Mice, Autoimmunity, Cathelicidins metabolism, Liver immunology, T-Lymphocytes, Regulatory immunology
- Abstract
Neutrophils with immunoregulatory properties, also referred to as type-2 neutrophils (N2), myeloid-derived suppressor cells (MDSCs), or tumor-associated neutrophils (TANs), comprise a heterogeneous subset of cells that arise from unknown precursors in response to poorly understood cues. Here, we find that, in several models of liver autoimmunity, pharmacologically induced, autoantigen-specific T regulatory type-1 (TR1) cells and TR1-cell-induced B regulatory (B
reg ) cells use five immunoregulatory cytokines to coordinately recruit neutrophils into the liver and program their transcriptome to generate regulatory neutrophils. The liver-associated neutrophils from the treated mice, unlike their circulating counterparts or the liver neutrophils of sick mice lacking antigen-specific TR1 cells, are proliferative, can transfer disease protection to immunocompromised hosts engrafted with pathogenic effectors, and blunt antigen-presentation and local autoimmune responses via cathelin-related anti-microbial peptide (CRAMP), a cathelicidin, in a CRAMP-receptor-dependent manner. These results, thus, identify antigen-specific regulatory T cells as drivers of tissue-restricted regulatory neutrophil formation and CRAMP as an effector of regulatory neutrophil-mediated immunoregulation., Competing Interests: Declaration of interests P. Santamaria is founder, scientific officer, and stockholder of Parvus Therapeutics. He is an inventor on patents on pMHC-based nanomedicines and receives funding from the company. D.A.A.V. is cofounder and stockholder in Novasenta, Tizona, and Potenza; a stockholder in Oncorus and Werewolf; has patents licensed and royalties received from Astellas and BMS; is a scientific advisory board member at Tizona, Werewolf, F-Star, and Bicara; is a consultant at Astellas, BMS, Almirall, and Incyte; and receives research funding from BMS, Astellas, and Novasenta., (Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF